Updates are available Correction dated 2016-11-14
Click to view Correction: https://doi.org/10.1038/ncomms13513
-
Authors
Chabon, Jacob J.
Simmons, Andrew D.
Lovejoy, Alexander F.
Esfahani, Mohammad S.
Newman, Aaron M.
Haringsma, Henry J.
Kurtz, David M.
Stehr, Henning
Scherer, Florian
Karlovich, Chris A.
Harding, Thomas C.
Durkin, Kathleen A.
Otterson, Gregory A.
Purcell, W. Thomas
Camidge, D. Ross
Goldman, Jonathan W.
Sequist, Lecia V.
Piotrowska, Zofia
Wakelee, Heather A.
Neal, Joel W.
Alizadeh, Ash A. https://orcid.org/0000-0002-5153-5625
Diehn, Maximilian https://orcid.org/0000-0003-2032-0581
- License Information
-
More Information
Article History
Received: 18 March 2016
Accepted: 3 May 2016
First Online: 10 June 2016
Change Date: 14 November 2016
Change Type: Update
Change Details: A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has not been fixed in the paper.
Competing interests
: A.M.N., A.A.A. and M.D. are co-inventors on patent applications, ‘An analytical platform for patient-specific profiling of circulating neoplastic DNA’ 14/209,807 and, ‘Practical Methods for Patient-Specific Tumour Markers for Disease Monitoring of Cancer’ PCT/US2015/049838, related to CAPP-Seq. A.M.N., A.A.A. and M.D. are consultants for Roche Molecular Diagnostics. A.D.S., C.A.K., H.J.H. and T.C.H. are employees of Clovis Oncology. C.A.K. has ownership interest in Clovis Oncology. Z.P. has received speakers bureau honoraria from Clovis Oncology. H.A.W. has received commercial research grants from Clovis Oncology. L.V.S. and J.W.N. are consultants for Clovis Oncology. The remaining authors declare no competing financial interests.
